Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies

Int J Mol Sci. 2022 Apr 27;23(9):4824. doi: 10.3390/ijms23094824.

Abstract

Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval.

Keywords: gene-targeting therapy; motor neuron disorders; muscular dystrophies.

Publication types

  • Review

MeSH terms

  • Genetic Therapy / methods
  • Humans
  • Motor Neuron Disease* / genetics
  • Motor Neuron Disease* / therapy
  • Muscular Atrophy, Spinal* / drug therapy
  • Muscular Atrophy, Spinal* / therapy
  • Muscular Dystrophy, Duchenne* / drug therapy
  • Muscular Dystrophy, Duchenne* / therapy
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / therapeutic use

Substances

  • Oligonucleotides, Antisense

Grant support

This research received no external funding.